NEW YORK, October 3, 2017 /PRNewswire/ --
If you want a Stock Review on MTBC, CERN, VEEV, or EVH then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com shifts focus on Medical Transcription Billing Corp. (NASDAQ: MTBC), Cerner Corp. (NASDAQ: CERN), Veeva Systems Inc. (NYSE: VEEV),
Medical Transcription Billing
On Monday, shares in New Jersey headquartered Medical Transcription Billing Corp. recorded a trading volume of 110,561 shares. The stock ended at $1.51, rising 2.72% from the last trading session. The Company's shares have gained 6.34% in the last one month, 15.27% over the previous three months, and 108.28% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.99% and 28.12%, respectively. Furthermore, shares of Medical Transcription Billing, which provides an integrated suite of Web-based solutions and related business services to healthcare providers primarily in the US, have a Relative Strength Index (RSI) of 56.64.
On September 28th, 2017, Medical Transcription Billing announced the closing of a public offering of 240,000 shares of its non-convertible Series A Cumulative Redeemable Perpetual Preferred Stock for $25 per share, for gross proceeds of $6 million. Access our complete research report on MTBC for free at:
Missouri headquartered Cerner Corp.'s stock finished yesterday's session 1.42% higher at $72.33. A total volume of 2.03 million shares was traded, which was above their three months average volume of 1.86 million shares. The Company's shares have gained 6.71% in the last one month, 10.43% over the previous three months, and 52.69% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.72% and 19.21%, respectively. Furthermore, shares of Cerner have an RSI of 69.61.
On September 19th, 2017, research firm RBC Capital Markets initiated a 'Top Pick' rating on the Company's stock, with a target price of $84 per share.
On September 26th, 2017, Cerner announced that it will host nearly 14,000 health care industry leaders, practitioners, and Company associates for its annual Cerner Health Conference to be held on October 09th, 2017, to October 12th, 2017 in Kansas City, Missouri. During the four-day event, attendees from around the globe will network to share best practices and gain hands-on experience with the Company's innovative health care solutions and services. The complimentary research report on CERN can be downloaded at:
At the close of trading on Monday, shares in California headquartered Veeva Systems Inc. climbed 1.19%, ending the day at $57.08. The stock recorded a trading volume of 1.10 million shares. The Company's shares have advanced 40.25% since the start of this year. The stock is trading 6.24% above its 200-day moving average. Moreover, shares of Veeva Systems, which provides cloud-based software for the life sciences industry in North America, Europe, Asia/Pacific, and internationally, have an RSI of 48.52.
On September 13th, 2017, Veeva Systems announced that Cancer Research UK selected Veeva Vault eTMF to modernize its clinical trial processes. The organization currently sponsors and manages approximately 25 early-phase oncology trials through its Centre for Drug Development. By improving regulatory compliance and increasing efficiency through active trial master file (TMF) management, Cancer Research UK aims to optimize development of new treatments for patients with cancer. Register for free on DailyStockTracker.com and get access to the latest report on VEEV at:
Virginia headquartered Evolent Health Inc.'s shares ended the day 5.06% higher at $18.70. A total volume of 2.57 million shares was traded, which was above their three months average volume of 1.41 million shares. The stock has gained 11.98% in the last month and 26.35% on an YTD basis. The Company's shares are trading 2.69% below their 50-day moving average. Additionally, shares of Evolent Health have an RSI of 54.61.
On September 20th, 2017, research firm KeyBanc Capital Markets initiated an 'Overweight' rating on the Company's stock, with a target price of $23 per share.
On September 27th, 2017, Evolent Health announced that it expects to significantly expand relationships with partners in Illinois and New Mexico. In Illinois, the Company expects to increase services to support a broader network, as CountyCare becomes one of the largest Medicaid managed care plans in the state. In New Mexico, the Company has entered into a unique agreement to acquire assets related to the commercial business from New Mexico Health Connections for $10.25 million in cash. Download your free research report on EVH at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All